NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2090.60 -2.00 (-0.10%)

609.8K NSE+BSE Volume

NSE 16 Dec, 2025 3:31 PM (IST)

95,498.4

Market Cap

High in industry

Beta 1Year

Average volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

11 Nov 2024

2090.60

-0.10%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,600/share.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

10 Nov 2024

2090.60

-0.10%

Superlative margin performance; US reversal likely in 3Q

Buy: Lupin Ltd.

Target

Emkay

Lupin’s 2QFY25 EBITDA/Adj PAT were 18%/26% ahead of our estimates (the magnitude of beat was broadly similar vs street estimates).

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

09 Nov 2024

2090.60

-0.10%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

08 Aug 2024

2090.60

-0.10%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the Stock

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

07 Aug 2024

2090.60

-0.10%

Strong Q1; complex products to drive growth

Buy: Lupin Ltd.

Target

Sharekhan

Q1FY2025 numbers were strong, beating our estimates on all fronts. Sales grew by 16% y-o-y to Rs. 5514 crore (9% above our estimates), on a 28% y-o-y growth in North America region to Rs. 2041 crore.

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

07 Aug 2024

2090.60

-0.10%

Strong beat; US/India drive earnings

Neutral: Lupin Ltd.

Target

Motilal Oswal

LPC delivered a strong earnings beat in 1QFY25, led by a superior show in key markets (US/India), lower R&D spending and a low tax rate.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

10 Jul 2024

2090.60

-0.10%

Launches critical for sustenance of turnaround

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

15 May 2024

2090.60

-0.10%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

08 May 2024

2090.60

-0.10%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the stock

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

08 May 2024

2090.60

-0.10%

Niche product drives earnings growth

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended
FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of
18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY). LPC continues to
implement efforts toward building a complex product pipeline in inhalation,
injectables and ophthalmics.

Lupin Ltd. is trading above all available SMAs

Is Lupin Ltd. worth buying?

933 Votes:

Buy 72.78%

Sell 17.58%

Hold 9.65%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf